HSBC Holdings
ALNY icon

HSBC Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

HSBC Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8M Hold
114,600
– – 0.02% 588
2025
Q4 		$46M Buy
+114,600
New +$50.7M 0.02% 514

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's ALNY Position: Q1 2026 in Review

HSBC Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 0.11% in Q1 2026, buying an estimated $34.7K and bringing the position to 89,619 shares worth $29.6M. The position accounts for 0.02% of the portfolio, ranked #644.

HSBC Holdings first reported a position in ALNY in Q4 2014 and has held it in 43 quarters since. The position peaked at $35.7M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • HSBC Holdings held 89,619 shares of Alnylam Pharmaceuticals worth $29.6M as of Q1 2026.
  • HSBC Holdings bought 102 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $34.7K.
  • Alnylam Pharmaceuticals made up 0.02% of HSBC Holdings's portfolio in Q1 2026, its #644 holding.
  • HSBC Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 43 quarters since.
  • HSBC Holdings's Alnylam Pharmaceuticals position peaked at $35.7M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.